CD8A and cancer: A similar observation was reported in patients with HCC treated with Nivolumab.[11e] Because the efficacy of ICIs and T‐cell‐based cancer immunotherapies relies on optimal activity of T cells in the TME[38] and CD8+ T cells are the major subsets for anticancer immunity,[39] our findings lay the groundwork for validating whether serum RNase1 can serve as a serum biomarker for predicting the efficacy of CD8+ T‐cell‐based cancer immunotherapies.